Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia

NCT01895452 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT01895452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01895452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2013
Completion date
June 30, 2016
Enrollment
291 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia